Viridian Therapeutics, Inc./DE
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $-26.5M | $-17.3M | $-11.3M | $-7.9M | $-2.2M |
| Depreciation & Amortization | $308.0K | $341.0K | $184.0K | $144.0K | $148.0K |
| Depreciation | — | — | — | — | — |
| Amortization | — | — | — | — | — |
| Stock-Based Compensation | $2.4M | $198.0K | $3.0M | $4.3M | — |
| Net Cash from Operating Activities | $-28.2M | $-14.8M | $-6.9M | $-2.2M | $-1.2M |
| Investing Activities | |||||
| Capital Expenditures | $246.0K | $250.0K | $123.0K | $266.0K | $5.0K |
| Business Acquisitions | — | — | — | — | — |
| Net Cash from Investing Activities | $1.0M | $-250.0K | $-95.0K | $-274.0K | $6.0K |
| Financing Activities | |||||
| Dividends Paid | — | — | — | — | — |
| Stock Repurchases | — | $2.0K | — | — | — |
| Net Cash from Financing Activities | $52.5M | $15.9M | $12.7M | $7.4M | $1.3M |
| Net Change in Cash | $25.3M | — | — | — | — |
| Free Cash Flow | $-28.4M | $-15.0M | $-7.0M | $-2.5M | $-1.2M |